PA
CLVS

Parallel Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Parallel Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed – – 3592
2022
Q3 		$0 Hold
100
– – ﹤0.01% 3627
2022
Q2 		$0 Hold
100
– – ﹤0.01% 3495
2022
Q1 		$0 Sell
100
-2,915
-97% -$5.73K ﹤0.01% 3401
2021
Q4 		$8K Buy
3,015
+2,915
+2,915% +$10.8K ﹤0.01% 2238
2021
Q3 		$0 Hold
100
– – ﹤0.01% 3361
2021
Q2 		$1K Hold
100
– – ﹤0.01% 2892
2021
Q1 		$1K Sell
100
-800
-89% -$5.36K ﹤0.01% 2740
2020
Q4 		$4K Hold
900
– – ﹤0.01% 2158
2020
Q3 		$5K Hold
900
– – ﹤0.01% 2064
2020
Q2 		$6K Buy
900
+100
+13% +$757 ﹤0.01% 1928
2020
Q1 		$5K Hold
800
– – ﹤0.01% 1931
2019
Q4 		$8K Hold
800
– – ﹤0.01% 1831
2019
Q3 		$3K Hold
800
– – ﹤0.01% 2114
2019
Q2 		$12K Sell
800
-49
-6% -$885 ﹤0.01% 1533
2019
Q1 		$21K Sell
849
-300
-26% -$7.52K ﹤0.01% 1207
2018
Q4 		$20K Buy
+1,149
New +$23.5K ﹤0.01% 1055

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Parallel Advisors's CLVS Position: Q4 2022 in Review

Parallel Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 100 shares.

Parallel Advisors first reported a position in CLVS in Q4 2018 and held it in 16 quarters. The position peaked at $21K in Q1 2019. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Parallel Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 100 Clovis Oncology, Inc. shares in Q4 2022.
  • Parallel Advisors first reported a position in Clovis Oncology, Inc. in Q4 2018 and held it in 16 quarters.
  • Parallel Advisors's Clovis Oncology, Inc. position peaked at $21K in Q1 2019.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.